AstraZeneca H1 and Q2 2022 Results Press Release

Our member AstraZeneca has announced their first half performance reports.  Big congratulations to them for their positive product development and financial surplus! 

On 29 July 2022, AstraZeneca launched a press release.  Pascal Soriot, Chief Executive Officer, commenting on the results said that they have been successful in terms of saving more than six million lives for their Covid-19 Vaxzevria, and have made great research contributions in sharing valuable practice-changing data for medicines, including Enhertu in breast cancer, Farxiga in heart failure and Ultomiris in neuromyelitis optica spectrum disorder. 

The SweCham would like to give a big shout out to AstraZeneca for their efforts in investing their financial success in a greater R&D to save more lives and to ensure sustainable growth! 

To read more, please visit https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2022/h1-2022-results.html  

Share:

More Posts

Event recap: CEO, Atlas Copco Group Webinar

Atlas Copco´s decentralised and collaboration-based approach to driving innovation and reaching sustainability goals has been at the heart of last week’s webinar. Over 100 participants participated

SweCham
Premium Plus Partners